Market Indices
Sector Heatmap
ORR — Militia Long/Short Equity ETF
NasdaqMilitia Long/Short Equity ETF
- O
- 38.41
- H
- 38.51
- L
- 38.24
- V
- 77.4K
ORR — Latest News & Headlines
20 StoriesORR Top Holdings List & Exposure (Militia Long/Short Equity ETF) - MarketBeat
ORR Top Holdings List & Exposure (Militia Long/Short Equity ETF) MarketBeat
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma - OncLive
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma OncLive
Trading Systems Reacting to (ORR) Volatility - Stock Traders Daily
Trading Systems Reacting to (ORR) Volatility Stock Traders Daily
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression - CancerNetwork
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression CancerNetwork
Weekly Recap: Rina‑S 45.9% ORR and Darwin Global 5.11% voting control - TradingView
Weekly Recap: Rina‑S 45.9% ORR and Darwin Global 5.11% voting control TradingView
OR Royalties Inc. (OR) Stock Price, News, Quote & History - Yahoo! Finance Canada
OR Royalties Inc. (OR) Stock Price, News, Quote & History Yahoo! Finance Canada
ORR announces lower investment fees for third parties and investors - Global Rail News
ORR announces lower investment fees for third parties and investors Global Rail News
Ray Davis Among Three Buffalo Bills' Players With Shrinking Roles Through Two Games - Sports Illustrated
Ray Davis Among Three Buffalo Bills' Players With Shrinking Roles Through Two Games Sports Illustrated
Cypherpunk Technologies (Nasdaq:CYPH) - Stock Analysis - Simply Wall Street
Cypherpunk Technologies (Nasdaq:CYPH) - Stock Analysis Simply Wall Street
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma - OncLive
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma OncLive
A matched ovarian cancer analysis found 38.7% response with a drug pair, versus 0% with usual care. - Stock Titan
A matched ovarian cancer analysis found 38.7% response with a drug pair, versus 0% with usual care. Stock Titan
Hailey Orr Named to American Banker's 2026 Most Powerful Women in Banking: NEXT List - www.marketscreener.com
Hailey Orr Named to American Banker's 2026 Most Powerful Women in Banking: NEXT List www.marketscreener.com
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer - CancerNetwork
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer CancerNetwork
BacTech Environmental Corporation to Attend the Centurion One Capital 4th Annual Bahamas Summit - The Globe and Mail
BacTech Environmental Corporation to Attend the Centurion One Capital 4th Annual Bahamas Summit The Globe and Mail
REG - Oriole Resources PLC - High-grade Limestone Confirmed at Wapouzé Project - TradingView
REG - Oriole Resources PLC - High-grade Limestone Confirmed at Wapouzé Project TradingView
Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC - CancerNetwork
Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC CancerNetwork
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer - OncLive
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer OncLive
This Insider Has Just Sold Shares In Power Corporation of Canada - Simply Wall Street
This Insider Has Just Sold Shares In Power Corporation of Canada Simply Wall Street
IGM Financial Insiders Sell CA$29m Of Stock, Possibly Signalling Caution - Simply Wall Street
IGM Financial Insiders Sell CA$29m Of Stock, Possibly Signalling Caution Simply Wall Street
Weiss upgrades Mitsubishi UFJ Financial Group stock to Buy - AD HOC NEWS
Weiss upgrades Mitsubishi UFJ Financial Group stock to Buy AD HOC NEWS